drugset / Trial / NCT00172341

Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children

NCT00172341 ↗

Phase 4 Unknown 100 enrolled National Taiwan University Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

Asthma, the airway inflammatory disorder, is an important chronic disease in children. About 10\~15% children are bothered with this. Allergens, such as house-dust mites (HDM), animal dander (i.e. cats and dogs), and seasonal pollens, are often implicated as causative and triggering factors of respiratory attacks in children with asthma. Among them, mites are the most common indoor allergen associated with asthma worldwide. It appears that SLIT is somewhat effective and safe. However, on the current evidence, further studies are needed to define the indications, the duration of treatment and therapeutic optimal dose of standardized allergen extracts in relation to efficacy and side effects before it is recommended for routine clinical use. The objective of the present study was to investigate the effects and safety of StaloralTM, the standardized extracts of D. pt. and D. f., in asthmatic children allergic to HDM.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject StaloralTM Unknown — Other

Indications